一、规模：创2022年以来新高，下半年进一步提速 政策支持叠加市场回暖下，2025年并购重组市场持续活跃，规模创2022年以来新高。并购重组作为高质量发展下推动资源整合的关键途径，以2024年9月 24日发布的"并购六条"为代表，政策支持推动并购重组市场持续活跃。2025年，随着资本市场持续回暖、企业转型加速，推动并购重组活跃度进一步提 升。2025年A股上市公司作为竞买方的并购重组案例共1527单，涉及规模达10158亿元，创2022年以来新高，较去年分别增长119单/1678亿元。 节奏上，2025年下半年企业并购重组进程加快。下半年，资本市场回暖步伐加快，为并购重组市场的进一步活跃奠定良好基础。2025年H1/H2并购重组数 量分别为665/862单，涉及规模分别达4174/5984亿元。 二、行业：新质生产力行业数量较多，传统行业贡献大规模并购 2025年，A股上市公司并购重组案例主要集中在新质生产力行业，部分传统行业贡献大规模并购案例。2025年，并购重组数量较多的行业主要包括化工、 电子、医药、机械设备、电力设备、汽车、计算机等，多为新质生产力行业，充分体现出在新质生产力驱动下，强链补链已成为并购 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) aims to promote convenient payment methods such as facial recognition, QR code scanning, mobile payments, and credit payments nationwide, targeting to make medical payment processes more convenient within approximately three years [1][3]. Group 1: Implementation Strategy - Local healthcare insurance departments will focus on addressing public concerns regarding long queues and multiple waiting times during medical visits [2][5]. - Patients will have the option to use various payment methods, including facial recognition, electronic medical insurance certificates, mobile payments, or credit payments, to achieve "seamless" and "rapid" payment experiences [2][5]. - Provincial healthcare insurance departments will prioritize better-performing cities for pilot programs, with at least two cities in each province to lead the initiative [2][5]. Group 2: Timeline and Coverage - By 2026, the first batch of pilot regions and designated medical institutions will implement convenient payment methods [2][5]. - By 2027, the initiative is expected to cover all coordinated areas within provinces [2][5]. - By 2028, all eligible designated medical institutions within provinces will fully adopt various convenient payment methods [2][5]. Group 3: Monitoring and Public Awareness - The NHSA will incorporate the implementation of convenient payment methods into the performance assessment of designated medical institutions, enhancing daily monitoring to ensure public benefits [2][5]. - The NHSA plans to promote this beneficial policy through various channels to ensure the public is informed and can utilize the new payment methods, thereby improving the medical experience [2][5].

Group 1 - The core viewpoint is that while there is a recognition of a potential bubble in AI, it is not yet at its final stage, indicating there is still room for growth [1] - The healthcare industry is viewed positively, with recommendations to buy since Q4 of last year and a maintained "overweight" stance starting June 2024 [1] - Most Chinese pharmaceutical companies are reported to have strong overseas profits, and the sector has been undervalued for a long time, with China leading in international patent applications and increasing its share in all technologies [1] Group 2 - Despite market expectations for the Federal Reserve to lower interest rates to 2.9% by the end of 2026, a final rate of 3.25% is anticipated [1] - Given the weakness of the US dollar, it is suggested to include some non-dollar bonds in investment portfolios for diversification [1] - An "overweight" stance on emerging market bonds is recommended, as they are expected to benefit from current market conditions [1]

Group 1 - Singapore has maintained a trade deficit with the US, amounting to $30 billion, since the signing of the free trade agreement in 2004, importing more than it exports [1][3] - The US announced a 10% tariff on Singaporean goods, despite Singapore's zero tariff policy, leading to strong backlash from Singaporean officials [1][3] - The Straits Times Index dropped 7.5% on April 7, 2025, marking the largest decline in over a decade, with predictions of potential negative growth in Singapore's economy for Q2 [5] Group 2 - Singapore's economy is heavily reliant on international trade, with total foreign trade exceeding three times its GDP [5] - The US's new tariff measures could significantly impact Singapore's pharmaceutical exports, which account for 13% of its total exports [7] - Singapore is exploring alternative strategies, such as rerouting chip exports through Vietnam to benefit from RCEP's zero-tariff channels, reflecting a shift in trade tactics [7]

Core Insights - JD Health has formed a deep collaboration with local innovative pharmaceutical company Kaiqi Xincheng Biopharmaceutical Technology Co., Ltd. to support the clinical cure of chronic hepatitis B patients in China [1][2] - The collaboration will leverage JD Health's strengths in medical services and instant retail, launching two innovative drugs: the first-class drug Adefovir Dipivoxil Tablets (brand name: Xinshumu®) and a zinc-selenium multivitamin soft capsule (brand name: Kaimumu®) [1][2] Drug Launch Details - Adefovir Dipivoxil Tablets (Xinshumu®) are designed for the treatment of adult chronic hepatitis B and have received support from national major new drug creation technology projects during the "12th Five-Year" and "13th Five-Year" plans [1] - Clinical trial results indicate that the drug effectively and persistently inhibits the virus, with a significantly higher proportion of patients achieving HBsAg levels below 1000 IU/mL compared to the control group (P<0.05) and other similar drugs [1] - The zinc-selenium multivitamin soft capsule (Kaimumu®) is formulated for liver nutrition and is rich in nine vitamins and two minerals, designed for easy absorption and convenient daily use [2] Service Integration - JD Health will utilize its ecosystem of "online consultation + pharmaceutical retail + instant delivery" to create a service loop that includes professional supply, online specialist guidance, and rapid delivery, facilitating the widespread availability of the new drugs [2] - Patients can purchase these new drugs through the JD APP or JD pharmacies nationwide with a valid prescription starting immediately [2] Strategic Goals - JD Health aims to enhance the overall efficiency and quality of the pharmaceutical supply chain through ongoing strategic collaboration with Kaiqi Xincheng, optimizing the patient experience [2] - The company is committed to providing high-quality pharmaceutical health products and services, contributing to the "Healthy China 2030" strategic goals by improving the accessibility of innovative drugs [3]

Market Overview - The A-share market showed mixed performance on January 8, with the Sci-Tech 50 Index rising by 1.77% and a half-day trading volume of 1.77 trillion, down by 701 billion from the previous trading day [1] - The Shanghai Composite Index increased by 0.09%, while the Shenzhen Component Index and the ChiNext Index fell by 0.2% and 0.52%, respectively [1] - Huachuang Securities believes the market is not extremely overheated, with trading volume and turnover rates indicating room for growth [1] Key Sectors Controlled Nuclear Fusion - The controlled nuclear fusion sector continued to show strength, with companies like China Nuclear Engineering and others achieving consecutive gains [3] - CITIC Securities noted that breakthroughs in high-temperature superconductors and AI technology are driving investment in large scientific facilities, creating significant opportunities in the upstream segment of the industry [3] Commercial Aerospace - The commercial aerospace sector experienced repeated strength, with companies such as Galaxy Electronics and others hitting their daily price limits [4] - Zhongtai Securities indicated that the commercial aerospace industry is entering a new phase of rapid development, with upcoming catalysts expected to enhance investment opportunities [4] Computing Power Chips - The computing power chip sector saw gains, with companies like Haiguang Information rising over 10% [5] - The Ministry of Industry and Information Technology, along with other departments, issued guidelines to strengthen AI computing power supply, promoting the development of intelligent chips and related technologies [5] Institutional Insights - CITIC Securities predicts a higher probability of upward market fluctuations in 2026, emphasizing the need for a balance between external and internal demand [7] - Zhongtai Securities maintains a cautiously optimistic view on the technology sector, suggesting that investors focus on specific sub-sectors with strong fundamentals [8] - Everbright Securities warns of increased market volatility due to profit-taking pressures, advising caution in investment strategies [9]

2026年1月7日，"踏浪前行 做多中国——全球重构下的中国资产机遇"华西证券2026年资本市场投资与产业年会在成都召开，华西证券党委副 书记、总裁杨炯洋致开幕辞，多位在蓉高管共同出席本次会议。 杨炯洋在致辞中向出席本次会议的嘉宾表示热烈欢迎。他指出，在全球格局深度重塑、"十五五"谋篇启章的关键阶段，"做多中国"需要坚定 的信念，更离不开成熟完备的资本市场和坚实的金融力量。本次会议以"踏浪前行 做多中国——全球重构下的中国资产机遇"为主题，力求以 长远视角挖掘中国资产价值，以开放姿态拥抱新发展格局，以专业力量助推资本市场高质量发展。他表示，作为一家专业的资本市场中介机 构、上市公司，华西证券积极响应国家战略部署，坚定推进"差异化发展、特色化经营"发展策略，致力于为客户提供定制化、全方位、全生 命周期的综合金融支持，助力企业客户把握区域一体化机遇深化发展。 杨炯洋向与会嘉宾介绍了华西证券业务布局。长期以来，公司聚焦"卖方研究、价值发现"，建立了一支具有较强品牌影响力和市场号召力的 卖方研究队伍，以及聚焦新一代信息技术、新材料、新消费、装备制造、医药健康五大方向的产业研究团队。华西证券实现了以直接股权投 资、定增 ...

Core Viewpoint - The A-share market is experiencing a mixed performance, with the Shanghai Composite Index showing slight gains while other indices like the Shenzhen Component and ChiNext are declining. The market is characterized by sector rotation and structural trends, suggesting a potential continuation of the bull market in A-shares due to favorable economic conditions and policy support [1]. Market Performance - On the morning of the 8th, the Shanghai Composite Index fluctuated within a narrow range, while the Sci-Tech Innovation 50 Index surged nearly 2%. Over 3,700 stocks in the A-share market were in the green [1]. - By midday, the Shanghai Composite Index rose by 0.09% to 4,089.45 points, the Shenzhen Component fell by 0.2%, and the ChiNext Index decreased by 0.52%. The Sci-Tech Innovation 50 Index increased by 1.77%. The total trading volume across the Shanghai, Shenzhen, and North markets reached approximately 1.78 trillion yuan [1]. Sector Performance - The brokerage, insurance, banking, and liquor sectors experienced declines, while the military, real estate, pharmaceuticals, and semiconductor sectors saw gains. Additionally, sectors related to industrial software, controllable nuclear fusion, and commercial aerospace were active [1]. Investment Strategy - According to Caixin Securities, the market is likely to shift towards a structural trend characterized by index fluctuations and sector rotation. Investors are advised to adopt a strategy of focusing on strong sectors while gradually adjusting to the rotation rhythm [1]. - Looking ahead, with resilient overseas economic conditions, likely continued loose dollar liquidity, ongoing domestic "dual easing" policies, and sustained inflation expectations due to "anti-involution," the bull market in A-shares is expected to continue [1].

Group 1 - Notable fund managers have disclosed their latest stock adjustments as the new year begins, with several companies announcing related updates [1] - Fund managers Ge Lan and Tang Xiaobin reduced their holdings in Kelun Pharmaceutical (002422), while Zhao Bei increased her stake [1][2] - Liu Yanchun and Hu Xinwei reduced their holdings in Proya (603605), while Zhou Yun entered the top ten shareholders of Jiazhe New Energy (601619) [1][6] Group 2 - As of December 31, 2025, Ge Lan's fund held 38.1954 million shares of Kelun Pharmaceutical, having reduced by 1.867 million shares compared to the previous quarter [2] - Tang Xiaobin's fund exited the top ten shareholders of Kelun Pharmaceutical by the end of 2025, having reduced holdings from 24.2335 million shares to 13.94 million shares [4] - Zhao Bei's fund increased its holdings in Kelun Pharmaceutical to 22 million shares, up by 2 million shares from the previous quarter [4] Group 3 - Liu Yanchun's fund held 2.6 million shares of Proya as of December 30, 2025, down from 3.332 million shares, indicating a reduction of over 700,000 shares [7] - Hu Xinwei's fund is no longer among the top ten shareholders of Proya [8] - Zhou Yun's fund and the National Social Security Fund 404 combination entered the top ten shareholders of Jiazhe New Energy in the fourth quarter of 2025 [9] Group 4 - The National Social Security Fund 114 combination increased its holdings in Nanshan Aluminum (600219) by 4.3432 million shares in the fourth quarter of 2025 [9] - By the end of 2025, five ETF products were included among the top ten shareholders of Nanshan Aluminum, indicating the growing influence of index funds [9] Group 5 - A significant increase in institutional research activities has been noted, with over 10,000 research sessions conducted in the past month, focusing on sectors such as semiconductors, general equipment, automotive, and artificial intelligence [10] - Fund managers are optimistic about the performance of non-financial listed companies in A-shares for 2025 and 2026, anticipating a stable recovery [10]

Group 1 - Lu Yan Pharmaceutical has achieved 8 consecutive limit-up trading days within 15 days, indicating strong market interest [1] - The stock reached a trading limit at 11:11 AM today with a transaction volume of 1.694 billion yuan and a turnover rate of 16.86% [1] - The recent fluctuations in the brain-computer interface sector have attracted market attention, with financing dynamics in related fields contributing to this interest [1] Group 2 - Lu Yan Pharmaceutical has acknowledged the importance of artificial intelligence and big data in the medical and pharmaceutical fields, indicating ongoing research and exploration in these areas [1] - The recent performance of the stock may be influenced by these technological advancements and their applications in the healthcare sector [1] - Investors are advised to be cautious of the volatility associated with consecutive limit-up stocks and to engage in rational investment practices [1]